Microsclerotherapy Treatment Comprehensive Study by Type (Sclerosants (Chromated Glycerin, Sodium Tetradecyl Sulfate, Polidocanol, Others), Micro-Needles, Graduated Compression Hosiery Supports, Others Surgical Products), Application (Hospitals, Cosmetic and Skin Clinics, Others) Players and Region - Global Market Outlook to 2030

Microsclerotherapy Treatment Market by XX Submarkets | Forecast Years 2022-2030  

  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Market Overview:
Growing incidence of spider veins as well as varicose veins will help to fuel global microsclerotherapy market. Microsclerotherapy is one of the finest technique to treat spider veins. Spider vein are also called as small varicose veins. They are produced because of the malfunctioning of the valves in the veins. Moderately painless technique, highly effective, minimal invasion, fewer post-operative complications, simple analgesic necessary during the process are the key drivers that will propel the evolution of the global market. Moreover, occurrence of unhealthy lifestyle, heredity, obesity are the factors that can influence the development of the global microsclerotherapy market during the forecast period.

Asia Pacific is projected to be the fastest-growing market, expanding at a CAGR of % from 2021 to 2030.

AttributesDetails
Study Period2018-2030
Base Year2021
Forecast Period2024-2030
Historical Period2018-2021
UnitValue (USD Million)
Key Companies ProfiledVein Clinics of America, Inc. (United States), STD Pharmaceutical Products Ltd (United Kingdom), Covidien (Ireland), Chemische Fabrik Kreussler & Co GmbH (Germany), Teleflex / Vascular Solutions, Inc. (United States), Medicetics (United Kingdom), Skin Care Clinic (United Kingdom) and Maryland Dermatology, Laser, Skin & Vein Institute (United States)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region or narrow down segments in the final scope subject to feasibility


AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics of major and emerging geographies across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Key Players of Microsclerotherapy Treatment Market Study:
Vein Clinics of America, Inc. (United States), STD Pharmaceutical Products Ltd (United Kingdom), Covidien (Ireland), Chemische Fabrik Kreussler & Co GmbH (Germany), Teleflex / Vascular Solutions, Inc. (United States), Medicetics (United Kingdom), Skin Care Clinic (United Kingdom) and Maryland Dermatology, Laser, Skin & Vein Institute (United States)

Microsclerotherapy Treatment Market Segment Analysis
ScopeSub-Segments
Application / End UserHospitals, Cosmetic and Skin Clinics and Others
TypeSclerosants [Chromated Glycerin, Sodium Tetradecyl Sulfate, Polidocanol, Others], Micro-Needles, Graduated Compression Hosiery Supports and Others Surgical Products


Influencing Trend:
Robust Research and Development Investments in Microsclerotherapy Treatment Development

Market Growth Drivers:
Rising Instances of Spider Veins and Varicose Veins and Introduction to Minimally Invasive Microsclerotherapy Treatment

Challenges:
Lack of Skilled Professionals related to Microsclerotherapy Treatment and Limited Availability of Resources in the Underdeveloped Regions

Restraints:
Comparatively Higher Cost of the Treatment and Availability of Number of Substitute Treatments to Microsclerotherapy Treatment

Opportunities:
Growing Prevalence of Unhealthier Lifestyles will lead to Increased Instances and Continuously Developing Healthcare Infrastructure

The Players having strong hold in the market are Vein Clinics of America, STD Pharmaceutical, Covidien, Chemische Fabrik Kreussler, and Teleflex / Vascular Solutions. Some of the other players that are also part of study are Vein Institute, LLC (United States) and Stratford Dermatherapy Clinic (United Kingdom). The Global Microsclerotherapy Treatment market is gaining huge competition due to involvement of United States companies that constantly invest in research & development to meet market expectation with new innovation.

Latest Industry Highlights:
In May 2022: THERACLION has announced the release of SONOVEIN HD, a scalable robotic system for non-invasive ecotherapy. This ground-breaking technology combines the first extracorporeal treatment ultrasound solution with the cutting-edge imaging capabilities of Hologic's acquisition of Supersonic Imagine.
In December 29, 2017 – Frazier Healthcare Partners (“Frazier”) is pleased announced the acquisition of a majority ownership stake in Vein Clinics of America (“VCA” orthe “Company”), the seventh platform investment for Frazier Healthcare Growth Buyout Fund and VIII.


Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Microsclerotherapy Treatment market.
In order to reach an exhaustive list of functional and relevant players, various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep into important geographies by players, and a thorough validation test is conducted to reach the most relevant players for survey in Microsclerotherapy Treatment market.
Identification of total players or companies operating in the global market which is further concentrated to fewer or most impacting players which are considered under the report’s scope. In order to make a priority list sorting is done based on revenue generated based on the latest reporting with the help of paid databases such as Factiva, Bloomberg, etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Microsclerotherapy Treatment Providers, Microsclerotherapy Drugs and Equipment Manufacturers, Hospital And Clinics, Healthcare Industry Associations, Government Agencies and Others.

This helps us to gather the data for the players’ revenue, operating cycle and expense, profit along with product or service growth, etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that include Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Type
  • Sclerosants [Chromated Glycerin, Sodium Tetradecyl Sulfate, Polidocanol, Others]
  • Micro-Needles
  • Graduated Compression Hosiery Supports
  • Others Surgical Products
By Application
  • Hospitals
  • Cosmetic and Skin Clinics
  • Others
By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Instances of Spider Veins and Varicose Veins
      • 3.2.2. Introduction to Minimally Invasive Microsclerotherapy Treatment
    • 3.3. Market Challenges
      • 3.3.1. Lack of Skilled Professionals related to Microsclerotherapy Treatment
      • 3.3.2. Limited Availability of Resources in the Underdeveloped Regions
    • 3.4. Market Trends
      • 3.4.1. Robust Research and Development Investments in Microsclerotherapy Treatment Development
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Microsclerotherapy Treatment, by Type, Application and Region (value) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Microsclerotherapy Treatment (Value)
      • 5.2.1. Global Microsclerotherapy Treatment by: Type (Value)
        • 5.2.1.1. Sclerosants [Chromated Glycerin, Sodium Tetradecyl Sulfate, Polidocanol, Others]
        • 5.2.1.2. Micro-Needles
        • 5.2.1.3. Graduated Compression Hosiery Supports
        • 5.2.1.4. Others Surgical Products
      • 5.2.2. Global Microsclerotherapy Treatment by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Cosmetic and Skin Clinics
        • 5.2.2.3. Others
      • 5.2.3. Global Microsclerotherapy Treatment Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. Microsclerotherapy Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Vein Clinics of America, Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. STD Pharmaceutical Products Ltd (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Covidien (Ireland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Chemische Fabrik Kreussler & Co GmbH (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Teleflex / Vascular Solutions, Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Medicetics (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Skin Care Clinic (United Kingdom)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Maryland Dermatology, Laser, Skin & Vein Institute (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Microsclerotherapy Treatment Sale, by Type, Application and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Microsclerotherapy Treatment (Value)
      • 7.2.1. Global Microsclerotherapy Treatment by: Type (Value)
        • 7.2.1.1. Sclerosants [Chromated Glycerin, Sodium Tetradecyl Sulfate, Polidocanol, Others]
        • 7.2.1.2. Micro-Needles
        • 7.2.1.3. Graduated Compression Hosiery Supports
        • 7.2.1.4. Others Surgical Products
      • 7.2.2. Global Microsclerotherapy Treatment by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Cosmetic and Skin Clinics
        • 7.2.2.3. Others
      • 7.2.3. Global Microsclerotherapy Treatment Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Microsclerotherapy Treatment: by Type(USD Million)
  • Table 2. Microsclerotherapy Treatment Sclerosants [Chromated Glycerin, Sodium Tetradecyl Sulfate, Polidocanol, Others] , by Region USD Million (2016-2021)
  • Table 3. Microsclerotherapy Treatment Micro-Needles , by Region USD Million (2016-2021)
  • Table 4. Microsclerotherapy Treatment Graduated Compression Hosiery Supports , by Region USD Million (2016-2021)
  • Table 5. Microsclerotherapy Treatment Others Surgical Products , by Region USD Million (2016-2021)
  • Table 6. Microsclerotherapy Treatment: by Application(USD Million)
  • Table 7. Microsclerotherapy Treatment Hospitals , by Region USD Million (2016-2021)
  • Table 8. Microsclerotherapy Treatment Cosmetic and Skin Clinics , by Region USD Million (2016-2021)
  • Table 9. Microsclerotherapy Treatment Others , by Region USD Million (2016-2021)
  • Table 10. South America Microsclerotherapy Treatment, by Country USD Million (2016-2021)
  • Table 11. South America Microsclerotherapy Treatment, by Type USD Million (2016-2021)
  • Table 12. South America Microsclerotherapy Treatment, by Application USD Million (2016-2021)
  • Table 13. Brazil Microsclerotherapy Treatment, by Type USD Million (2016-2021)
  • Table 14. Brazil Microsclerotherapy Treatment, by Application USD Million (2016-2021)
  • Table 15. Argentina Microsclerotherapy Treatment, by Type USD Million (2016-2021)
  • Table 16. Argentina Microsclerotherapy Treatment, by Application USD Million (2016-2021)
  • Table 17. Rest of South America Microsclerotherapy Treatment, by Type USD Million (2016-2021)
  • Table 18. Rest of South America Microsclerotherapy Treatment, by Application USD Million (2016-2021)
  • Table 19. Asia Pacific Microsclerotherapy Treatment, by Country USD Million (2016-2021)
  • Table 20. Asia Pacific Microsclerotherapy Treatment, by Type USD Million (2016-2021)
  • Table 21. Asia Pacific Microsclerotherapy Treatment, by Application USD Million (2016-2021)
  • Table 22. China Microsclerotherapy Treatment, by Type USD Million (2016-2021)
  • Table 23. China Microsclerotherapy Treatment, by Application USD Million (2016-2021)
  • Table 24. Japan Microsclerotherapy Treatment, by Type USD Million (2016-2021)
  • Table 25. Japan Microsclerotherapy Treatment, by Application USD Million (2016-2021)
  • Table 26. India Microsclerotherapy Treatment, by Type USD Million (2016-2021)
  • Table 27. India Microsclerotherapy Treatment, by Application USD Million (2016-2021)
  • Table 28. South Korea Microsclerotherapy Treatment, by Type USD Million (2016-2021)
  • Table 29. South Korea Microsclerotherapy Treatment, by Application USD Million (2016-2021)
  • Table 30. Taiwan Microsclerotherapy Treatment, by Type USD Million (2016-2021)
  • Table 31. Taiwan Microsclerotherapy Treatment, by Application USD Million (2016-2021)
  • Table 32. Australia Microsclerotherapy Treatment, by Type USD Million (2016-2021)
  • Table 33. Australia Microsclerotherapy Treatment, by Application USD Million (2016-2021)
  • Table 34. Rest of Asia-Pacific Microsclerotherapy Treatment, by Type USD Million (2016-2021)
  • Table 35. Rest of Asia-Pacific Microsclerotherapy Treatment, by Application USD Million (2016-2021)
  • Table 36. Europe Microsclerotherapy Treatment, by Country USD Million (2016-2021)
  • Table 37. Europe Microsclerotherapy Treatment, by Type USD Million (2016-2021)
  • Table 38. Europe Microsclerotherapy Treatment, by Application USD Million (2016-2021)
  • Table 39. Germany Microsclerotherapy Treatment, by Type USD Million (2016-2021)
  • Table 40. Germany Microsclerotherapy Treatment, by Application USD Million (2016-2021)
  • Table 41. France Microsclerotherapy Treatment, by Type USD Million (2016-2021)
  • Table 42. France Microsclerotherapy Treatment, by Application USD Million (2016-2021)
  • Table 43. Italy Microsclerotherapy Treatment, by Type USD Million (2016-2021)
  • Table 44. Italy Microsclerotherapy Treatment, by Application USD Million (2016-2021)
  • Table 45. United Kingdom Microsclerotherapy Treatment, by Type USD Million (2016-2021)
  • Table 46. United Kingdom Microsclerotherapy Treatment, by Application USD Million (2016-2021)
  • Table 47. Netherlands Microsclerotherapy Treatment, by Type USD Million (2016-2021)
  • Table 48. Netherlands Microsclerotherapy Treatment, by Application USD Million (2016-2021)
  • Table 49. Rest of Europe Microsclerotherapy Treatment, by Type USD Million (2016-2021)
  • Table 50. Rest of Europe Microsclerotherapy Treatment, by Application USD Million (2016-2021)
  • Table 51. MEA Microsclerotherapy Treatment, by Country USD Million (2016-2021)
  • Table 52. MEA Microsclerotherapy Treatment, by Type USD Million (2016-2021)
  • Table 53. MEA Microsclerotherapy Treatment, by Application USD Million (2016-2021)
  • Table 54. Middle East Microsclerotherapy Treatment, by Type USD Million (2016-2021)
  • Table 55. Middle East Microsclerotherapy Treatment, by Application USD Million (2016-2021)
  • Table 56. Africa Microsclerotherapy Treatment, by Type USD Million (2016-2021)
  • Table 57. Africa Microsclerotherapy Treatment, by Application USD Million (2016-2021)
  • Table 58. North America Microsclerotherapy Treatment, by Country USD Million (2016-2021)
  • Table 59. North America Microsclerotherapy Treatment, by Type USD Million (2016-2021)
  • Table 60. North America Microsclerotherapy Treatment, by Application USD Million (2016-2021)
  • Table 61. United States Microsclerotherapy Treatment, by Type USD Million (2016-2021)
  • Table 62. United States Microsclerotherapy Treatment, by Application USD Million (2016-2021)
  • Table 63. Canada Microsclerotherapy Treatment, by Type USD Million (2016-2021)
  • Table 64. Canada Microsclerotherapy Treatment, by Application USD Million (2016-2021)
  • Table 65. Mexico Microsclerotherapy Treatment, by Type USD Million (2016-2021)
  • Table 66. Mexico Microsclerotherapy Treatment, by Application USD Million (2016-2021)
  • Table 67. Company Basic Information, Sales Area and Its Competitors
  • Table 68. Company Basic Information, Sales Area and Its Competitors
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Microsclerotherapy Treatment: by Type(USD Million)
  • Table 76. Microsclerotherapy Treatment Sclerosants [Chromated Glycerin, Sodium Tetradecyl Sulfate, Polidocanol, Others] , by Region USD Million (2025-2030)
  • Table 77. Microsclerotherapy Treatment Micro-Needles , by Region USD Million (2025-2030)
  • Table 78. Microsclerotherapy Treatment Graduated Compression Hosiery Supports , by Region USD Million (2025-2030)
  • Table 79. Microsclerotherapy Treatment Others Surgical Products , by Region USD Million (2025-2030)
  • Table 80. Microsclerotherapy Treatment: by Application(USD Million)
  • Table 81. Microsclerotherapy Treatment Hospitals , by Region USD Million (2025-2030)
  • Table 82. Microsclerotherapy Treatment Cosmetic and Skin Clinics , by Region USD Million (2025-2030)
  • Table 83. Microsclerotherapy Treatment Others , by Region USD Million (2025-2030)
  • Table 84. South America Microsclerotherapy Treatment, by Country USD Million (2025-2030)
  • Table 85. South America Microsclerotherapy Treatment, by Type USD Million (2025-2030)
  • Table 86. South America Microsclerotherapy Treatment, by Application USD Million (2025-2030)
  • Table 87. Brazil Microsclerotherapy Treatment, by Type USD Million (2025-2030)
  • Table 88. Brazil Microsclerotherapy Treatment, by Application USD Million (2025-2030)
  • Table 89. Argentina Microsclerotherapy Treatment, by Type USD Million (2025-2030)
  • Table 90. Argentina Microsclerotherapy Treatment, by Application USD Million (2025-2030)
  • Table 91. Rest of South America Microsclerotherapy Treatment, by Type USD Million (2025-2030)
  • Table 92. Rest of South America Microsclerotherapy Treatment, by Application USD Million (2025-2030)
  • Table 93. Asia Pacific Microsclerotherapy Treatment, by Country USD Million (2025-2030)
  • Table 94. Asia Pacific Microsclerotherapy Treatment, by Type USD Million (2025-2030)
  • Table 95. Asia Pacific Microsclerotherapy Treatment, by Application USD Million (2025-2030)
  • Table 96. China Microsclerotherapy Treatment, by Type USD Million (2025-2030)
  • Table 97. China Microsclerotherapy Treatment, by Application USD Million (2025-2030)
  • Table 98. Japan Microsclerotherapy Treatment, by Type USD Million (2025-2030)
  • Table 99. Japan Microsclerotherapy Treatment, by Application USD Million (2025-2030)
  • Table 100. India Microsclerotherapy Treatment, by Type USD Million (2025-2030)
  • Table 101. India Microsclerotherapy Treatment, by Application USD Million (2025-2030)
  • Table 102. South Korea Microsclerotherapy Treatment, by Type USD Million (2025-2030)
  • Table 103. South Korea Microsclerotherapy Treatment, by Application USD Million (2025-2030)
  • Table 104. Taiwan Microsclerotherapy Treatment, by Type USD Million (2025-2030)
  • Table 105. Taiwan Microsclerotherapy Treatment, by Application USD Million (2025-2030)
  • Table 106. Australia Microsclerotherapy Treatment, by Type USD Million (2025-2030)
  • Table 107. Australia Microsclerotherapy Treatment, by Application USD Million (2025-2030)
  • Table 108. Rest of Asia-Pacific Microsclerotherapy Treatment, by Type USD Million (2025-2030)
  • Table 109. Rest of Asia-Pacific Microsclerotherapy Treatment, by Application USD Million (2025-2030)
  • Table 110. Europe Microsclerotherapy Treatment, by Country USD Million (2025-2030)
  • Table 111. Europe Microsclerotherapy Treatment, by Type USD Million (2025-2030)
  • Table 112. Europe Microsclerotherapy Treatment, by Application USD Million (2025-2030)
  • Table 113. Germany Microsclerotherapy Treatment, by Type USD Million (2025-2030)
  • Table 114. Germany Microsclerotherapy Treatment, by Application USD Million (2025-2030)
  • Table 115. France Microsclerotherapy Treatment, by Type USD Million (2025-2030)
  • Table 116. France Microsclerotherapy Treatment, by Application USD Million (2025-2030)
  • Table 117. Italy Microsclerotherapy Treatment, by Type USD Million (2025-2030)
  • Table 118. Italy Microsclerotherapy Treatment, by Application USD Million (2025-2030)
  • Table 119. United Kingdom Microsclerotherapy Treatment, by Type USD Million (2025-2030)
  • Table 120. United Kingdom Microsclerotherapy Treatment, by Application USD Million (2025-2030)
  • Table 121. Netherlands Microsclerotherapy Treatment, by Type USD Million (2025-2030)
  • Table 122. Netherlands Microsclerotherapy Treatment, by Application USD Million (2025-2030)
  • Table 123. Rest of Europe Microsclerotherapy Treatment, by Type USD Million (2025-2030)
  • Table 124. Rest of Europe Microsclerotherapy Treatment, by Application USD Million (2025-2030)
  • Table 125. MEA Microsclerotherapy Treatment, by Country USD Million (2025-2030)
  • Table 126. MEA Microsclerotherapy Treatment, by Type USD Million (2025-2030)
  • Table 127. MEA Microsclerotherapy Treatment, by Application USD Million (2025-2030)
  • Table 128. Middle East Microsclerotherapy Treatment, by Type USD Million (2025-2030)
  • Table 129. Middle East Microsclerotherapy Treatment, by Application USD Million (2025-2030)
  • Table 130. Africa Microsclerotherapy Treatment, by Type USD Million (2025-2030)
  • Table 131. Africa Microsclerotherapy Treatment, by Application USD Million (2025-2030)
  • Table 132. North America Microsclerotherapy Treatment, by Country USD Million (2025-2030)
  • Table 133. North America Microsclerotherapy Treatment, by Type USD Million (2025-2030)
  • Table 134. North America Microsclerotherapy Treatment, by Application USD Million (2025-2030)
  • Table 135. United States Microsclerotherapy Treatment, by Type USD Million (2025-2030)
  • Table 136. United States Microsclerotherapy Treatment, by Application USD Million (2025-2030)
  • Table 137. Canada Microsclerotherapy Treatment, by Type USD Million (2025-2030)
  • Table 138. Canada Microsclerotherapy Treatment, by Application USD Million (2025-2030)
  • Table 139. Mexico Microsclerotherapy Treatment, by Type USD Million (2025-2030)
  • Table 140. Mexico Microsclerotherapy Treatment, by Application USD Million (2025-2030)
  • Table 141. Research Programs/Design for This Report
  • Table 142. Key Data Information from Secondary Sources
  • Table 143. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Microsclerotherapy Treatment: by Type USD Million (2016-2021)
  • Figure 5. Global Microsclerotherapy Treatment: by Application USD Million (2016-2021)
  • Figure 6. South America Microsclerotherapy Treatment Share (%), by Country
  • Figure 7. Asia Pacific Microsclerotherapy Treatment Share (%), by Country
  • Figure 8. Europe Microsclerotherapy Treatment Share (%), by Country
  • Figure 9. MEA Microsclerotherapy Treatment Share (%), by Country
  • Figure 10. North America Microsclerotherapy Treatment Share (%), by Country
  • Figure 11. Global Microsclerotherapy Treatment share by Players 2021 (%)
  • Figure 12. Global Microsclerotherapy Treatment share by Players (Top 3) 2021(%)
  • Figure 13. Global Microsclerotherapy Treatment share by Players (Top 5) 2021(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Vein Clinics of America, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 16. Vein Clinics of America, Inc. (United States) Revenue: by Geography 2021
  • Figure 17. STD Pharmaceutical Products Ltd (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 18. STD Pharmaceutical Products Ltd (United Kingdom) Revenue: by Geography 2021
  • Figure 19. Covidien (Ireland) Revenue, Net Income and Gross profit
  • Figure 20. Covidien (Ireland) Revenue: by Geography 2021
  • Figure 21. Chemische Fabrik Kreussler & Co GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 22. Chemische Fabrik Kreussler & Co GmbH (Germany) Revenue: by Geography 2021
  • Figure 23. Teleflex / Vascular Solutions, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 24. Teleflex / Vascular Solutions, Inc. (United States) Revenue: by Geography 2021
  • Figure 25. Medicetics (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 26. Medicetics (United Kingdom) Revenue: by Geography 2021
  • Figure 27. Skin Care Clinic (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 28. Skin Care Clinic (United Kingdom) Revenue: by Geography 2021
  • Figure 29. Maryland Dermatology, Laser, Skin & Vein Institute (United States) Revenue, Net Income and Gross profit
  • Figure 30. Maryland Dermatology, Laser, Skin & Vein Institute (United States) Revenue: by Geography 2021
  • Figure 31. Global Microsclerotherapy Treatment: by Type USD Million (2025-2030)
  • Figure 32. Global Microsclerotherapy Treatment: by Application USD Million (2025-2030)
  • Figure 33. South America Microsclerotherapy Treatment Share (%), by Country
  • Figure 34. Asia Pacific Microsclerotherapy Treatment Share (%), by Country
  • Figure 35. Europe Microsclerotherapy Treatment Share (%), by Country
  • Figure 36. MEA Microsclerotherapy Treatment Share (%), by Country
  • Figure 37. North America Microsclerotherapy Treatment Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Vein Clinics of America, Inc. (United States)
  • STD Pharmaceutical Products Ltd (United Kingdom)
  • Covidien (Ireland)
  • Chemische Fabrik Kreussler & Co GmbH (Germany)
  • Teleflex / Vascular Solutions, Inc. (United States)
  • Medicetics (United Kingdom)
  • Skin Care Clinic (United Kingdom)
  • Maryland Dermatology, Laser, Skin & Vein Institute (United States)
Additional players considered in the study are as follows:
Vein Institute, LLC (United States) , Stratford Dermatherapy Clinic (United Kingdom)
Select User Access Type

Key Highlights of Report


Jan 2024 186 Pages 74 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

"Robust Research and Development Investments in Microsclerotherapy Treatment Development" is seen as one of major influencing trends for Microsclerotherapy Treatment Market during projected period 2021-2030.
The Concentration Rate of Global Microsclerotherapy Treatment market is highlighted using HHI Index.
United States Players will contribute the maximum growth of Global Microsclerotherapy Treatment market throughout the predicted period.
North Amercia holds highest share for Microsclerotherapy Treatment Market .

Know More About Global Microsclerotherapy Treatment Market Report?